Menu
Recruiting NCT05109208

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

No phase Interventional Prostate Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ulrasound Vibroelastography (UVE).
Who it may be relevant to
Registry conditions: Prostate Adenocarcinoma. Basic parameters: from 40 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Ultrasound Vibroelastography in Post-Prostatectomy Erectile Dysfunction

Overview

Researchers are trying to determine whether there is additional utility to using vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile function (recovery) after prostate cancer surgery.

Interventions

  • Diagnostic test Ulrasound Vibroelastography (UVE)
    Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).

Primary outcome measures

  • Change in Viscoelasticity [Time frame: Baseline, 3 months, 6 months and 9 months post-prostatectomy]

Eligibility criteria

Inclusion criteria include:

  • Age > 40 years
  • Clinically localized prostate cancer (American Urological Association Grade Groups 1-2; cT1c or cT2a-b; PSA < 10) without clinic or imaging evidence of localized extra-prostatic or metastatic disease (i.e. AUA low and favorable intermediate risk prostate cancer)
  • International Index of Erectile Function (IIEF) of ≥ 21 points at baseline (no or mild erectile dysfunction)
  • Patient-expressed interest in consultation for sexual function (erectile function) preservation/ optimization
  • Planned bilateral nerves-paring prostatectomy

Exclusion criteria include:

  • Moderate or severe ED based in IIEF criteria (score < 21)
  • History of prior pelvic or penile surgery
  • Current or prior androgen deprivation therapy
  • Planned non-nerve sparing prostatectomy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Health services research

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT05109208 · 21-001713

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗